Qualigen Therapeutics, Inc. (QLGN)

US — Healthcare Sector
Peers: NBY  ATHE  QNRX  ARTL  SONN  ISPC  PTPI  KTTA  ADTX 

Automate Your Wheel Strategy on QLGN

With Tiblio's Option Bot, you can configure your own wheel strategy including QLGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol QLGN
  • Rev/Share 0.0
  • Book/Share 22.7569
  • PB 0.1276
  • Debt/Equity 0.0
  • CurrentRatio 1.0111
  • ROIC -8.0631

 

  • MktCap 4747471.0
  • FreeCF/Share -4899.2521
  • PFCF -0.6655
  • PE -0.0006
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 7.4167

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Qualigen Therapeutics, Inc. (QLGN)

  • IPO Date 2015-06-23
  • Website https://qlgntx.com
  • Industry Biotechnology
  • CEO Kevin A. Richardson II
  • Employees 4

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.